Why Wolfe Research Remains Bullish on Eli Lilly and Company (LLY) and Its Obesity Pipeline

We recently compiled a list of the 10 Most Widely Held Stocks by Individuals in 2026. Eli Lilly and Company (NYSE:LLY) is also one of the most widely held stock by individuals.

TheFly reported on May 21 that Wolfe Research maintained an Outperform rating on LLY and kept its $1,350 price target unchanged. The firm highlighted late-stage Phase 3 data for retatrutide, showing strong weight reduction outcomes, reaching up to 26.1% at 80 weeks and exceeding 30% in longer follow-up among higher-body-mass participants. The results also showed meaningful improvements across key cardiometabolic health indicators. Wolfe Research said these findings reinforce LLY’s leadership position in GLP-1-based obesity treatments and strengthen its differentiation in the competitive metabolic disease space. The firm further noted that the drug candidate may help set a new standard for future obesity therapies aimed at higher efficacy benchmarks.

Why Wolfe Research Remains Bullish on Eli Lilly and Company (LLY) and Its Obesity Pipeline

Separately, on May 20, Engage Biologics confirmed that Eli Lilly and Company (NYSE:LLY) had acquired it in a transaction valued at up to $202 million in cash. The deal includes an upfront payment along with additional milestone-based payments tied to future development achievements. Engage Biologics is working on the Tethosome platform, a non-viral DNA delivery technology designed to address challenges in gene delivery such as limited potency, reduced tolerability, and restrictions on repeat dosing.

The acquisition is intended to support the advancement of this platform by integrating it into Lilly’s broader research and development efforts in genetic medicine and advanced therapeutic delivery systems.

Eli Lilly and Company (NYSE:LLY) is a U.S.-based pharmaceutical firm that develops and manufactures prescription medicines in areas like cardiometabolic diseases, oncology, immunology, and neuroscience.

While we acknowledge the risk and potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LLY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1